Novavax (NASDAQ:NVAX – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Volatility & Risk
Novavax has a beta of 2.65, suggesting that its share price is 165% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500.
Valuation & Earnings
This table compares Novavax and Xenetic Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Novavax | $1.12 billion | 1.28 | $440.30 million | ($0.46) | -18.90 |
| Xenetic Biosciences | $2.98 million | 1.33 | -$2.68 million | ($1.16) | -1.49 |
Novavax has higher revenue and earnings than Xenetic Biosciences. Novavax is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations for Novavax and Xenetic Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Novavax | 3 | 2 | 5 | 0 | 2.20 |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Novavax presently has a consensus price target of $12.33, suggesting a potential upside of 41.84%. Given Novavax’s stronger consensus rating and higher probable upside, research analysts clearly believe Novavax is more favorable than Xenetic Biosciences.
Insider and Institutional Ownership
53.0% of Novavax shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Novavax and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Novavax | -18.64% | -14.82% | -7.55% |
| Xenetic Biosciences | -75.90% | -40.62% | -34.97% |
Summary
Novavax beats Xenetic Biosciences on 11 of the 14 factors compared between the two stocks.
About Novavax
Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its technology combines recombinant protein-based vaccine antigens with Matrix-M, a saponin-based adjuvant designed to strengthen the immune response. The company’s best-known product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in the United States and other markets. Novavax also develops additional vaccine candidates, including a combination COVID-19 and influenza vaccine. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax serves international markets through regulatory approvals and commercial partnerships.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for oncology indications. The company’s primary focus is its XCART platform, an autologous cell-therapy technology designed to modify a patient’s own T cells to recognize and attack cancer cells. Xenetic has applied the XCART platform to potential treatments for B-cell malignancies, including programs intended to target specific antigens found on cancerous B cells. The company’s research and development activities have centered on advancing personalized immunotherapies through preclinical and clinical development.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
